Evidence map›Paper›PMID 38501559›Full record

ArticleAnnals of clinical and translational neurology2024

Exploring the neurological features of individuals with germline PTEN variants: A multicenter study.

Andrew Dhawan, Sarah Baitamouni, Darren Liu, Robyn Busch, Patricia Klaas, Thomas W Frazier, Siddharth Srivastava, Sumit Parikh, Gary E Hsich, Neil R Friedman and 5 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Annals of clinical and translational neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Update on Pediatric Surveillance Recommendations for PTEN Hamartoma Tumor Syndrome, DICER1-Related Tumor Predisposition, and Tuberous Sclerosis Complex.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Andrew DhawanGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.ORCID 0000-0002-5027-1277
Sarah BaitamouniGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
Darren LiuGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
Robyn BuschDepartment of Neurology and Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.ORCID 0000-0002-5442-4912
Patricia KlaasDepartment of Neurology and Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
Thomas W FrazierDepartment of Psychology, John Carroll University, University Heights, Ohio, 44118, USA.
Siddharth SrivastavaDepartment of Neurology, Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, 02115, USA.ORCID 0000-0001-7008-1879
Sumit ParikhDepartment of Pediatric Neurology, Cleveland Clinic Children's, Cleveland, Ohio, USA.
Gary E HsichDepartment of Pediatric Neurology, Cleveland Clinic Children's, Cleveland, Ohio, USA.
Neil R FriedmanClinical Transformation, Barrow Neurological Institute, Phoenix Children's Hospital - Thomas Campus, Phoenix, Arizona, 85016, USA.
David M RitterDivisions of Neurology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, 45229, USA.ORCID 0000-0001-7723-3636
Antonio Y HardanDepartment of Child Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, California, 94305, USA.
Julian A Martinez-AgostoDepartment of Human Genetics, UCLA, Los Angeles, California, 90095, USA.ORCID 0000-0001-6776-6949
Mustafa SahinDepartment of Neurology, Rosamund Stone Zander Translational Neuroscience Center, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, 02115, USA.ORCID 0000-0001-7044-2953
Charis EngGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, 44195, USA.
Cleveland Clinic · USBoston Children's Hospital · USCleveland Clinic Lerner College of Medicine · USBarrow Neurological Institute · USCincinnati Children's Hospital Medical Center · USJohn Carroll University · USPalo Alto University · USUniversity of California, Los Angeles · US

Funding

Toward better characterization and clinical trial readiness for targeting neuropsychiatric manifestations in PTEN pathogenic variantsU54NS092090 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI ALEXANDER KOLEVZON · 2014 to 2026
$20.1M
Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SCOTT Loren POMEROY, MUSTAFA SAHIN · 2021 to 2026
$9.4M
ACTION OF ANTI I-A ANTIBODIES IN SUPPRESSION OF EAEK07NS000920 · NINDS · UNIVERSITY OF VERMONT &ST AGRIC COLLEGE · PI SRIRAM, SUBRAMANIAM · 1985 to 1989
–
NCATS NIH HHSNICHD NIH HHS P50 HD105351NIH HHS U54NS0920NIMH NIH HHSNINDS NIH HHS U54 NS092090
6 · The paper itself

Abstract

objectivePTEN, a known tumor suppressor gene, is a mediator of neurodevelopment. Individuals with germline pathogenic variants in the PTEN gene, molecularly defined as PTEN hamartoma tumor syndrome (PHTS), experience a variety of neurological and neuropsychiatric challenges during childhood, including autism spectrum disorder (ASD). However, the frequency and nature of seizures and the utilization of allied health services have not been described.

methodsYoung patients with PHTS and sibling controls were recruited across five centers in the United States and followed every 6-12 months for a mean of 2.1 years. In addition to the history obtained from caregivers, neurodevelopmental evaluations and structured dysmorphology examinations were conducted, and brain MRI findings, received therapies, and epilepsy characteristics were reported.

resultsOne hundred and seven patients with PHTS (median age 8.7 years; range 3-21 years) and 38 controls were enrolled. ASD and epilepsy were frequent among patients with PHTS (51% and 15%, respectively), with generalized epilepsy strongly associated with ASD. Patients with epilepsy often required two antiseizure medications. Neuroimaging revealed prominent perivascular spaces and decreased peritrigonal myelination in individuals with PHTS-ASD. Allied therapy use was frequent and involved physical, occupational, speech, and social skills therapies, with 89% of all patients with PHTS, regardless of ASD diagnosis, utilizing at least one service.

interpretationThis prospective, longitudinal study highlights the wide neurological spectrum seen in young individuals with PHTS. ASD is common in PHTS, comorbid with epilepsy, and allied health services are used universally. Our findings inform care discussions with families about neurological outcomes in PHTS.

Indexed as

Autism Spectrum DisorderEpilepsyGerm-Line MutationPTEN PhosphohydrolaseAdolescentAdultChildChild, PreschoolFemaleHamartoma Syndrome, MultipleHumansMaleYoung AdultPTEN Phosphohydrolase

Identifiers

PMID38501559
PMCPMC11093251
OpenAlexW4392955983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.